{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Myeloproliferative+Neoplasms+%28MPNs%29", "query": { "condition": "Myeloproliferative Neoplasms (MPNs)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 14, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Myeloproliferative+Neoplasms+%28MPNs%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-22T04:14:16.621Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05423691", "title": "Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myelofibrosis" ], "interventions": [ { "name": "CK0804", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cellenkos, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2022-12-27", "completion_date": "2026-12-30", "has_results": false, "last_update_posted_date": "2025-04-13", "last_synced_at": "2026-05-22T04:14:16.621Z", "location_count": 4, "location_summary": "Sacramento, California • New York, New York • The Bronx, New York + 1 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "The Bronx", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05423691" }, { "nct_id": "NCT04605211", "title": "A Distress Reduction Intervention for Patients With BCR-ABL-Negative MPNs or CML on Tyrosine Kinase Inhibitors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Myeloproliferative Neoplasm", "Chronic Phase Chronic Myelogenous Leukemia", "Chronic Myeloid Leukemia" ], "interventions": [ { "name": "Online Mindfulness Meditation", "type": "BEHAVIORAL" }, { "name": "Internet-Based Webinars", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "OTHER" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2020-09-18", "completion_date": "2022-09-30", "has_results": false, "last_update_posted_date": "2023-02-13", "last_synced_at": "2026-05-22T04:14:16.621Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04605211" }, { "nct_id": "NCT04103645", "title": "Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib in Treating Anemic MPN Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myeloproliferative Neoplasm" ], "interventions": [ { "name": "Vactosertib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2019-11-22", "completion_date": "2024-07-10", "has_results": true, "last_update_posted_date": "2025-07-02", "last_synced_at": "2026-05-22T04:14:16.621Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04103645" }, { "nct_id": "NCT06661915", "title": "A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Accelerated Phase Myeloproliferative Neoplasm", "Blast Phase Myeloproliferative Neoplasm", "Essential Thrombocythemia", "Myelodysplastic/Myeloproliferative Neoplasm", "Myeloproliferative Neoplasm, Not Otherwise Specified", "Polycythemia Vera", "Primary Myelofibrosis", "Secondary Myelofibrosis" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Decitabine and Cedazuridine", "type": "DRUG" }, { "name": "Iadademstat", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 62, "start_date": "2025-08-14", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-05-13", "last_synced_at": "2026-05-22T04:14:16.621Z", "location_count": 31, "location_summary": "Irvine, California • Orange, California • Palo Alto, California + 27 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Coral Gables", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06661915" }, { "nct_id": "NCT02718300", "title": "A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "MPN (Myeloproliferative Neoplasms)" ], "interventions": [ { "name": "Parsaclisib", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 74, "start_date": "2017-02-08", "completion_date": "2022-04-29", "has_results": true, "last_update_posted_date": "2024-05-01", "last_synced_at": "2026-05-22T04:14:16.621Z", "location_count": 39, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Berkeley, California + 33 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Berkeley", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02718300" }, { "nct_id": "NCT06291987", "title": "Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myeloproliferative Neoplasms" ], "interventions": [ { "name": "Ivosidenib", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2024-09-19", "completion_date": "2026-05", "has_results": false, "last_update_posted_date": "2025-11-05", "last_synced_at": "2026-05-22T04:14:16.621Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06291987" }, { "nct_id": "NCT07362225", "title": "MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Polycythemia Vera", "ET (Essential Thrombocythemia)", "Polycythemia Vera (PV)", "Essential Thrombocythemia (ET)", "Primary Myelofibrosis (MF)", "Primary Myelofibrosis (PMF)", "Myelofibrosis", "Myelofibrosis (MF)", "Myelofibrosis, Primary", "Myelofibrosis, Post ET", "Myelofibrosis, Post PV", "Myelofibrosis (PMF)", "Myelofibrosis，MF", "Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis", "Myelofibrosis Due to and Following Polycythemia Vera", "Myelofibrosis Transformation in Essential Thrombocythemia", "Myelofibrosis With High Molecular Risk Mutations", "MF", "Secondary Myelofibrosis", "Secondary Myelofibrosis in Myeloproliferative Disease", "Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis)", "Post-Polycythemia Vera Myelofibrosis", "Post-polycythemia Vera Myelofibrosis (PPV-MF)", "Post-polycythemia Vera Myelofibrosis (Post-PV MF)", "Post-polycythemia Vera Myelofibrosis(Post-PV MF)", "Post-PV MF", "Post-Essential Thrombocythemia Myelofibrosis", "Post-essential Thrombocythemia Myelofibrosis (PET-MF)", "Post-essential Thrombocythemia Myelofibrosis(Post-ET MF)", "Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)", "Post-ET MF", "Pre-fibrotic Myelofibrosis", "Myeloproliferative Disorder", "Myeloproliferative Disorders", "Myeloproliferative Disorders (MPD)", "Myeloproliferative Neoplasms (MPNs)", "Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis", "Myeloproliferative Neoplasm With 10% Blasts or Higher", "Myeloproliferative Neoplasms", "MPN", "MPN (Myeloproliferative Neoplasms)", "MPN-associated Myelofibrosis", "Myeloproliferative Neoplasm, Unclassifiable", "Myeloproliferative Neoplasm, Not Otherwise Specified", "Accelerated Phase MPN", "Accelerated Phase Myeloproliferative Neoplasm", "Blast Phase MPN", "Blast Phase Myeloproliferative Neoplasm", "Thrombocythemia Myelofibrosis (PET-MF)", "Thrombocythemia, Essential", "Thrombocythemia, Hemorrhagic", "Agnogenic Myeloid Metaplasia", "Chronic Idiopathic Myelofibrosis", "Idiopathic Myelofibrosis", "MDS/MPN Crossover Syndromes" ], "interventions": [], "intervention_types": [], "sponsor": "MPN Research Foundation", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5000, "start_date": "2025-09-26", "completion_date": "2035-09-08", "has_results": false, "last_update_posted_date": "2026-01-23", "last_synced_at": "2026-05-22T04:14:16.621Z", "location_count": 2, "location_summary": "Chicago, Illinois • New York, New York", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07362225" }, { "nct_id": "NCT05177211", "title": "Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myeloproliferative Neoplasm", "Chronic Neutrophilic Leukemia", "MDS" ], "interventions": [ { "name": "Fedratinib Pill", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2022-03-01", "completion_date": "2026-04", "has_results": true, "last_update_posted_date": "2026-04-17", "last_synced_at": "2026-05-22T04:14:16.621Z", "location_count": 3, "location_summary": "Tampa, Florida • Ann Arbor, Michigan • Cleveland, Ohio", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05177211" }, { "nct_id": "NCT03326310", "title": "Selumetinib and Azacitidine in High Risk Chronic Blood Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Myeloid Leukemia", "Myelofibroses" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" }, { "name": "Selumetinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2018-09-04", "completion_date": "2027-09-04", "has_results": false, "last_update_posted_date": "2025-12-29", "last_synced_at": "2026-05-22T04:14:16.621Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03326310" }, { "nct_id": "NCT07469891", "title": "A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Polycythemia Vera (PV)", "Myelofibrosis (MF)", "Myeloproliferative Neoplasms (MPNs)", "Post-Polycythemia Vera Myelofibrosis", "Post-Essential Thrombocythemia Myelofibrosis", "Primary Myelofibrosis (PMF)" ], "interventions": [ { "name": "PRT12396", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Prelude Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2026-04-29", "completion_date": "2028-04", "has_results": false, "last_update_posted_date": "2026-05-14", "last_synced_at": "2026-05-22T04:14:16.621Z", "location_count": 2, "location_summary": "Coral Springs, Florida • Grand Rapids, Michigan", "locations": [ { "city": "Coral Springs", "state": "Florida" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT07469891" } ] }